New Risk • Jul 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$39.1m market cap, or US$27.8m). Reported Earnings • May 22
First quarter 2026 earnings released: EPS: CA$0.017 (vs CA$0.007 in 1Q 2025) First quarter 2026 results: EPS: CA$0.017 (up from CA$0.007 in 1Q 2025). Revenue: CA$5.00m (up 9.8% from 1Q 2025). Net income: CA$1.23m (up 149% from 1Q 2025). Profit margin: 25% (up from 11% in 1Q 2025). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Declared Dividend • Apr 22
Dividend of CA$0.005 announced Shareholders will receive a dividend of CA$0.005. Ex-date: 24th April 2026 Payment date: 28th April 2026 Dividend yield will be 3.8%, which is about the same as the industry average. Sustainability & Growth Dividend is not covered by earnings (101% earnings payout ratio). However, it is well covered by cash flows (23% cash payout ratio). The dividend has decreased over the past 46 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to grow by 12% to bring the payout ratio under control. However, EPS has declined by 13% over the last 5 years so the company would need to reverse this trend. Ankündigung • Apr 21
NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026 NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026. New Risk • Apr 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 40% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$25.6m market cap, or US$18.4m). Reported Earnings • Apr 05
Full year 2025 earnings released: EPS: CA$0.015 (vs CA$0.006 in FY 2024) Full year 2025 results: EPS: CA$0.015 (up from CA$0.006 in FY 2024). Revenue: CA$17.9m (up 8.8% from FY 2024). Net income: CA$1.29m (up 210% from FY 2024). Profit margin: 7.2% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Ankündigung • Apr 02
NexgenRx Inc., Annual General Meeting, May 21, 2026 NexgenRx Inc., Annual General Meeting, May 21, 2026. Declared Dividend • Dec 14
Dividend of CA$0.005 announced Shareholders will receive a dividend of CA$0.005. Ex-date: 17th December 2025 Payment date: 19th December 2025 Dividend yield will be 3.8%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by both earnings (57% earnings payout ratio) and cash flows (47% cash payout ratio). The dividend has decreased over the past 46 years, indicating a lack of growth and stability in payments. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend. Ankündigung • Dec 12
NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025 NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025. Reported Earnings • Nov 23
Third quarter 2025 earnings released: EPS: CA$0.008 (vs CA$0.002 in 3Q 2024) Third quarter 2025 results: EPS: CA$0.008 (up from CA$0.002 in 3Q 2024). Revenue: CA$4.62m (up 11% from 3Q 2024). Net income: CA$589.8k (up 295% from 3Q 2024). Profit margin: 13% (up from 3.6% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Ankündigung • Aug 19
NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025 NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025. Reported Earnings • Aug 15
Second quarter 2025 earnings released: EPS: CA$0.005 (vs CA$0 in 2Q 2024) Second quarter 2025 results: EPS: CA$0.005 (up from CA$0 in 2Q 2024). Revenue: CA$4.35m (up 8.7% from 2Q 2024). Net income: CA$353.5k (up CA$321.6k from 2Q 2024). Profit margin: 8.1% (up from 0.8% in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Ankündigung • Apr 18
Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025 NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025. Ankündigung • Mar 28
NexgenRx Inc., Annual General Meeting, May 15, 2025 NexgenRx Inc., Annual General Meeting, May 15, 2025. Declared Dividend • Nov 29
Dividend of CA$0.005 announced Dividend of CA$0.005 is the same as last year. Ex-date: 16th December 2024 Payment date: 20th December 2024 Dividend yield will be 3.4%, which is lower than the industry average of 3.8%. Sustainability & Growth Dividend is not covered by earnings (350% earnings payout ratio). However, it is covered by cash flows (66% cash payout ratio). The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to grow by 289% to bring the payout ratio under control, which is more than the 45% EPS growth achieved over the last 5 years. Ankündigung • Nov 26
Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024 NexgenRx Inc. announced a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of the Company's outstanding common shares. The dividend will be payable on or before December 20, 2024 to all shareholders of record as at the close of business on December 16, 2024. Reported Earnings • Nov 26
Third quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.002 loss in 3Q 2023) Third quarter 2024 results: EPS: CA$0.002 (up from CA$0.002 loss in 3Q 2023). Revenue: CA$4.16m (up 23% from 3Q 2023). Net income: CA$149.2k (up CA$280.0k from 3Q 2023). Profit margin: 3.6% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance. Ankündigung • Oct 01
NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of Directors NexgenRx Inc. announced the appointment of Linda Brennan to its Board of Directors effective immediately. Linda Brennan currently serves as Chief Financial Officer, Corporate Secretary and a Director of PJX Resources Inc. Ms. Brennan has been a consultant for 12 years, providing strategic advice and organizing and structuring financings to numerous early stage companies in the junior resource sector. She brings knowledge of finance, accounting and public markets to NexgenRx. She has served in the capacity of corporate secretary for several TSX-V listed companies. Ms. Brennan holds Business Administration and Bachelor of Commerce degrees from the University of Victoria and Royal Roads University, respectively. New Risk • Aug 18
New major risk - Revenue and earnings growth Earnings have declined by 5.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 5.8% per year over the past 5 years. Minor Risks Paying a dividend despite being loss-making. Market cap is less than US$100m (CA$18.5m market cap, or US$13.5m). Reported Earnings • Aug 18
Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2023) Second quarter 2024 results: EPS: CA$0 (in line with 2Q 2023). Revenue: CA$4.08m (up 19% from 2Q 2023). Net income: CA$31.9k (up CA$40.5k from 2Q 2023). Profit margin: 0.8% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Declared Dividend • Jun 19
Dividend of CA$0.005 announced Dividend of CA$0.005 is the same as last year. Ex-date: 24th June 2024 Payment date: 30th June 2024 Dividend yield will be 3.6%, which is lower than the industry average of 3.8%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (76% cash payout ratio). The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Ankündigung • Jun 15
NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024 NEXGENRX INC. announced that a dividend in the amount of $0.005 has been declared in respect of all of its outstanding common shares. This dividend will be payable on or before June 30, 2024 to all shareholders of record as at the close of business on June 24, 2024. Reported Earnings • May 19
First quarter 2024 earnings released: EPS: CA$0.006 (vs CA$0.003 in 1Q 2023) First quarter 2024 results: EPS: CA$0.006 (up from CA$0.003 in 1Q 2023). Revenue: CA$4.29m (up 24% from 1Q 2023). Net income: CA$460.9k (up 137% from 1Q 2023). Profit margin: 11% (up from 5.6% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Ankündigung • May 18
Charles Burns Tenders Resignation as Director of NexgenRx Inc NexgenRx Inc. announced that at the annual and special meeting of shareholders held on May 16, 2024, one of the Directors, Charles Burns was duly elected although the number of votes 'Withheld' exceeded the number of votes cast 'For' his election and based on the Company's Majority Voting Policy, Mr. Burns has tendered his resignation as a director of the Company. The Board has determined to delay acceptance of Mr. Burns' resignation until such time as a qualified candidate can be appointed to fill the vacancy created by this resignation, which is expected to occur on or before September 30, 2024. Reported Earnings • Apr 07
Full year 2023 earnings released: CA$0.005 loss per share (vs CA$0 in FY 2022) Full year 2023 results: CA$0.005 loss per share (further deteriorated from CA$0 in FY 2022). Revenue: CA$13.8m (up 8.3% from FY 2022). Net loss: CA$332.0k (loss widened CA$309.6k from FY 2022). Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Ankündigung • Apr 03
NexgenRx Inc., Annual General Meeting, May 16, 2024 NexgenRx Inc., Annual General Meeting, May 16, 2024. Board Change • Jan 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Randy McGlynn was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Dec 30
NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors NEXGENRX INC. announced the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive role in the industry and as such will be devoting 100% of his time to this new endeavour. Ankündigung • Dec 21
NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024 NEXGENRX INC announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before January 4, 2024 to all shareholders of record as at the close of business on December 29, 2023. Reported Earnings • Nov 24
Third quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.001 loss in 3Q 2022) Third quarter 2023 results: CA$0.002 loss per share (further deteriorated from CA$0.001 loss in 3Q 2022). Revenue: CA$3.39m (up 2.2% from 3Q 2022). Net loss: CA$130.7k (loss widened 102% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 23
Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2022) Second quarter 2023 results: EPS: CA$0 (in line with 2Q 2022). Revenue: CA$3.42m (up 10.0% from 2Q 2022). Net loss: CA$8.6k (down 129% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Ankündigung • Jun 16
NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023 NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before June 30, 2023 to all shareholders of record as at the close of business on June 23, 2023. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding. Board Change • May 25
High number of new directors Director Dave Bennett was the last director to join the board, commencing their role in 2023. Reported Earnings • May 20
First quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.005 in 1Q 2022) First quarter 2023 results: EPS: CA$0.003 (down from CA$0.005 in 1Q 2022). Revenue: CA$3.46m (up 9.0% from 1Q 2022). Net income: CA$194.9k (down 44% from 1Q 2022). Profit margin: 5.6% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • May 19
NexgenRx Inc. Appoints Dave Bennett as New Director NexgenRx Inc. at its AGM held on May 19, 2023, approved the election of Mr. Dave Bennett as new director. Mr. Bennett is a seasoned senior executive and actuary with more than 30 years' experience working in the life insurance and wealth management industries. Most recently, he was at The Equitable Life of Canada, where he led the Group Benefits business for six years. Prior to that, he was the Chief Financial Officer of the company, responsible for all financial oversight, strategic planning and corporate business development. He also has extensive experience in strategy, with time spent at McKinsey & Co, and led the Mergers and Acquisitions function at Manulife. Mr. Bennett attained his ICD.D in 2022 and has served on a number of not-for-profit boards such as Grand River Hospital, the Waterloo District School Board, and as the Chair of an independent school. He also has considerable experience working with boards as management, having been accountable to the Audit and Pension committees of Equitable Life's Board of Directors for 7 years, and leading strategic reviews. Board Change • Apr 25
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Randy McGlynn was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 08
Full year 2022 earnings released Full year 2022 results: Revenue: CA$12.8m (up 7.9% from FY 2021). Net loss: CA$22.4k (down 101% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Board Change • Feb 23
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Randy McGlynn was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buying Opportunity • Jan 27
Now 23% undervalued Over the last 90 days, the stock is up 27%. The fair value is estimated to be CA$0.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 75%. Reported Earnings • Dec 02
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: CA$3.32m (up 16% from 3Q 2021). Net loss: CA$64.6k (down 115% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Randy McGlynn was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Sep 25
NexgenRx Inc. Announces Dividend on its outstanding common shares, payable on or Before October 10, 2022 NexgenRx Inc. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding series 1 preferred shares. This dividend will be payable on or before October 10, 2022 to all shareholders of record as at the close of business on October 3, 2022. As of the date of this press release, there are a total of 6,600,000 series 1 preferred shares issued and outstanding. Reported Earnings • Aug 19
Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.005 profit in 2Q 2021) Second quarter 2022 results: CA$0.001 loss per share (down from CA$0.005 profit in 2Q 2021). Revenue: CA$3.11m (up 13% from 2Q 2021). Net loss: CA$35.9k (down 110% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 18
First quarter 2022 earnings released: EPS: CA$0.005 (vs CA$0.005 in 1Q 2021) First quarter 2022 results: EPS: CA$0.005 (vs CA$0.005 in 1Q 2021). Revenue: CA$3.17m (up 13% from 1Q 2021). Net income: CA$378.0k (up 14% from 1Q 2021). Profit margin: 12% (in line with 1Q 2021). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Board Change • Apr 28
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Randy McGlynn was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Apr 07
NexgenRx Inc., Annual General Meeting, May 19, 2022 NexgenRx Inc., Annual General Meeting, May 19, 2022. Reported Earnings • Mar 28
Full year 2021 earnings released: EPS: CA$0.055 (vs CA$0.029 in FY 2020) Full year 2021 results: EPS: CA$0.055 (up from CA$0.029 in FY 2020). Revenue: CA$11.8m (up 12% from FY 2020). Net income: CA$3.89m (up 90% from FY 2020). Profit margin: 33% (up from 19% in FY 2020). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 21
Third quarter 2021 earnings released: EPS CA$0.006 (vs CA$0.007 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CA$2.86m (up 8.0% from 3Q 2020). Net income: CA$429.6k (down 16% from 3Q 2020). Profit margin: 15% (down from 19% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Board Change • Sep 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Randy McGlynn was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Aug 19
Second quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.007 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CA$2.76m (up 15% from 2Q 2020). Net income: CA$380.1k (down 21% from 2Q 2020). Profit margin: 14% (down from 20% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 29
First quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.004 in 1Q 2020) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: CA$2.80m (down 2.5% from 1Q 2020). Net income: CA$362.1k (up 27% from 1Q 2020). Profit margin: 13% (up from 9.9% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 03
Full year 2020 earnings released: EPS CA$0.03 (vs CA$0.003 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CA$11.0m (up 16% from FY 2019). Net income: CA$2.12m (up CA$2.32m from FY 2019). Profit margin: 19% (up from net loss in FY 2019). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 23
New 90-day high: CA$0.34 The company is up 70% from its price of CA$0.20 on 24 November 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Insurance industry, which is up 6.0% over the same period. Is New 90 Day High Low • Jan 27
New 90-day high: CA$0.30 The company is up 100% from its price of CA$0.15 on 29 October 2020. The Canadian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Insurance industry, which is up 21% over the same period. Is New 90 Day High Low • Nov 28
New 90-day high: CA$0.23 The company is up 35% from its price of CA$0.17 on 28 August 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Insurance industry, which is up 9.0% over the same period. Reported Earnings • Nov 21
Third quarter 2020 earnings released: EPS CA$0.007 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: CA$2.65m (up 19% from 3Q 2019). Net income: CA$509.8k (up CA$728.6k from 3Q 2019). Profit margin: 19% (up from net loss in 3Q 2019). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Ankündigung • Jul 20
NexgenRx Inc.(TSXV:NXG) dropped from S&P/TSX Venture Composite Index NexgenRx Inc.(TSXV:NXG) dropped from S&P/TSX Venture Composite Index 
